Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a research report released on Monday morning.

Several other equities research analysts have also recently issued reports on NTLA. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. William Blair restated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Wedbush reaffirmed a “neutral” rating and set a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. The Goldman Sachs Group reissued a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a report on Friday. Finally, Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday. Two research analysts have rated the stock with a sell rating, six have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.12.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $9.45 on Monday. Intellia Therapeutics has a 52 week low of $8.96 and a 52 week high of $33.28. The firm’s 50-day simple moving average is $10.80 and its 200 day simple moving average is $15.46. The firm has a market cap of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 over the last 90 days. 3.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in Intellia Therapeutics during the 4th quarter valued at approximately $25,000. Sterling Capital Management LLC raised its stake in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after buying an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics in the fourth quarter valued at $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics during the fourth quarter valued at $43,000. Finally, Jones Financial Companies Lllp grew its holdings in Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after acquiring an additional 2,280 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.